To truly make a dent on a global scale, digital health startups must recognize the importance of creating highly structured and personalized evidence-based behavioral therapies to tackle specific risky health behaviors.
N-of-1 trials are a unique trial design which can inform personalized evidence-based decisions for the patient when data from traditional clinical trials are lacking or not generalizable.
The success of such an approach requires a radical transformation — from simply collecting, storing and relaying information back to users to intelligently processing the data collected to help recommend highly personalized, evidence-based techniques, designed to nudge behaviors in the right direction.
We felt that IMPACT could be its sister in depression care management because of its focus on screening, measurement, and personalized, evidence-based guideline care.
As well as using DNA methylation as a biomarker for personalizing chemotherapy, evidence has emerged that detection of abnormal promoter CpG island hypermethylation is also a potential biomarker for risk of developing cancer.
Traditional randomized controlled trials and statistical methods are not designed to discover if, when, and to whom an intervention should be applied; thus, other methodological approaches are needed that allow for the practice of personalized, evidence-based medicine with patients with bipolar depression.
The field of biomedical informatics is rapidly approaching the era of personalized, evidence-based and multispectral medicine.
APT was both evidence based and personalized to current symptoms, prior treatment history, and course of illness (Suppes et al. 2005).
The present findings demonstrate that handheld presentation of clinical evidence should be personalized according to the requirements and preferences of different types of physicians.
We specifically elucidate the conflicts arising from an evidence-based versus personalized medicine approach in addressing unmet medical needs in a rare disease such as LN.
